Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serplulimab + anlotinib
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Serplulimab plus anlotinib is a combination regimen consisting of serplulimab, a humanized IgG4 monoclonal antibody targeting the programmed cell death protein 1 (PD-1) immune checkpoint, and anlotinib, an oral small-molecule multi-targeted tyrosine kinase inhibitor (TKI) that inhibits angiogenesis and tumor growth by targeting VEGFR1-3, FGFR1-4, PDGFRα/β, and c-Kit. This combination is being investigated in clinical trials, primarily in China, for various oncology indications, including extensive-stage small cell lung cancer (ES-SCLC) and advanced esophageal squamous cell carcinoma (ESCC). The combination leverages the synergistic effects of immune checkpoint blockade and anti-angiogenesis to enhance anti-tumor immune responses and remodel the tumor microenvironment.
- Other names
- HLX10 + AL3818HLX10 + anlotinibserplulimab + AL3818serplulimab + anlotinib hydrochlorideserplulimab plus anlotinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on serplulimab + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serplulimab + anlotinib.